“…The potential drugs include histone deacetylase (HDAC) inhibitors such as sodium butyrate [ 41 ], phenylbutyrate [ 42 ], valproic acid (VPA) [ 43 ], trichostatin A [ 44 ], SAHA [ 45 ], and LBH589 [ 46 ], as well as hydroxyuria [ 47 ], sodium vanadate [ 48 ], aclarubicin [ 49 ], indoprofen [ 50 ], bortezomib [ 51 ], and aminoglycosides, such as tobramycin, amikacin [ 52 ], TC007 [ 53 ], and G418 [ 54 ]. Since there are still no drugs that have shown consistent benefits in clinical trials [ 55 , 56 ], finding an effective treatment with distinct therapeutic mechanisms, such as SMN independent targets, is necessary for future SMA therapy.…”